One of the more intriguing observations in this issue is from a small-scale survey of acupuncture students and practitioners mentioned in an article by James Giordano, Joan Engebretson, and Mary Garcia, "Challenges to Complementary and Alternative Medical Research: Focal Issues Influencing Integration Into a Cancer Care Model." These practitioners of an ancient traditional medicine system expressed reluctance toward becoming integrated with conventional medicine, based on their perception that such cooptation could lead to a loss of some of their core values regarding scope of practice and underlying theory. I suspect that they may have been reacting to several things that might occur in the integration of alternative therapies into conventional practice. The fear of cooptation probably arises from the perception that the intellectual credit for a complementary and alternative medicine (CAM) therapy may settle on the conventional practitioners who adopt it, who thereafter seem to somehow "own" the therapy, rather than on those who originated and maintained the practice itself-not unlike the situation in which rich-country researchers investigate the traditional medicine of an indigenous group, formulate a drug based on it, and make millions of dollars, while the indigenous people continue to suffer neglect and poverty. The Convention on Biological Diversity is now remedying the latter situation, but there is no convention governing what happens to the discipline of acupuncture when physicians can go to a short training program, learn to needle a few points, and open an "integrative medicine practice" without a global understanding of traditional Chinese medicine and its approach to health, let alone how it relates to Western approaches.
Another major concern in attempting to integrate traditional medicine practices into Western medicine through evidence-based research, which might have disturbed the acupucturists in Giordano's article, is the loss of the multidimensional approaches to health that seems inevitable as such practices are subjected to the intellectual meat grinder of the randomized clinical trial system. Giordano points out the limitations of the randomized clinical trial and discusses the difficulties of applying it to broader conceptualizations of health, such as those found in traditional medical approaches. It is axiomatic that a good clinical trial is built around a single outcome variable. Without a single variable as the focus of the project, it is impossible to calculate the correct size for the experimental and control groups in the trial. But traditional approaches-and integrative therapy-very typically address health in a multidimensional framework, often with substantial attention to individualization of therapies based on various assessments of health and illness. Another example of such a traditional approach in this issue appears in the Integrative Tumor Board contribution of medical herbalist David Winston. Winston sets out 6 goals for herbal therapy with a melanoma patient, with a different selection of herbs to address each goal. Which of these would be the correct goal to explore in a randomized trial of such a therapy? Would it make sense to disaggregate the goals and explore each one separately? It seems to me quite likely that the different goals actually support each other and would not be successful when applied individually or without the dietary intervention that Winston proposes as a foundation for his herbal therapies. But where is the questionnaire/assessment instrument that would serve as a single clinical variable measuring quality of life-survival-pain relieffreedom from cancer recurrence-infection resistance for which most traditional and integrative practices aim? Nowhere, of course! This is one of the problems that Giordano and colleagues attempt to address in their article, using a model of heterodox healing originally proposed by Joan Engebretson. They discuss the use of different types of data and studies that range from the causal outcome study to the correlational or even acausal/noetic study, and they advocate an approach to CAM research in which evidence may range from experimental, mechanistic studies to qualitative observational studies of salutogenic variables, depending on the meaning sought and the context of the observation.
Another concern they address is the need for crosstraining in CAM and in conventional medicine and particularly in research techniques applicable to CAM and traditional medicine systems. Medical students both desire and greatly benefit from significant contact with CAM practitioners during their training. Medical schools around the country are confronting this reality. Medical student leaders from 5 schools in the Chicago area recently joined forces to sponsor a symposium on CAM in which several CAM Editorial practitioners as well as integratively oriented physicians were invited to give presentations and to interact with the students. This was, in part, an effort that they hoped would alert the faculty of their schools to their real need to learn about CAM and integrative medicine. Giordano points out, on the other hand, that there are many CAM instructional facilities in the United States; most of these are privately held, small institutions that emphasize instruction over research. The faculty and students of these institutions need training in research techniques as well as contact with conventional physicians. It is critical to consider their input in the design of research studies on CAM, but without understanding the research endeavor, they are likely to be unable to contribute to study design as much as would be optimal.
Giordano thus advocates more contact between medical students and CAM practitioners, as well as specific training in research methods in the CAM instructional schools, a position that deserves applause. Without working on education, authentic interaction, contact, and mutual understanding, we risk having a situation that is seen at some integrative medical centers in which conventional and CAM practitioners practice under one roof but in basic ignorance of each other's approaches to healing. In research, we run the risk of cultural clashes that can waste millions of dollars of research funding, such as the difficulties described by Hammer and Jonas in an earlier article in this journal which focused on efforts by the National Institutes of Health (NIH) to conduct a randomized trial of the antineoplaston therapies of Stanislaw Burzynski. 1 Burzynski's therapy is not one of the complex, lifestyle-based CAM approaches, being more pharmacological in nature. Even without the problem of dealing with a multidimensional integrative system, though, the trial foundered on a series of conflicts and misunderstandings between the National Cancer Institute and Burzynski, including patient selection, evaluation, production of antineoplastons, the role of Burzynski in the trial, and other objective issues. Underlying these issues, however, was a basic problem of trust, power, and affiliation between the NIH and Burzynski. This problem has the potential to crop up in any situation in which a member of the research community acts as the investigator and the traditional or alternative practitioner becomes the "lab rat" instead of a collaborator or at least a figure whose status in his or her own right is regarded equivalent to that of the researcher. Clearly, efforts must be made on both sides to level the playing field with more significant contact, education, and collaboration as traditional, alternative, or integrative practices are investigated.
Xiaojuan Shu, Michael McCulloch, and colleagues present a meta-analysis that in some ways exemplifies what Giordano discusses. This group, consisting of scientists along with licensed acupuncturists who are currently taking scientific training, has performed a metaanalysis on randomized trials conducted in China on traditional Chinese herbal formulas given as adjuncts to chemotherapy for liver cancer. They have access to and the ability to read and interpret the Chinese herbal literature that most medical schools in the United States and Europe lack and were consequently able to assemble a rather large database of studies. The studies, however, employ a dizzying array of different herbal therapies and combinations, and while Shu and colleagues do find a significant positive effect on survival in patients using herbal therapies (combined with chemotherapy) versus those using only chemotherapy, the ultimate result is somewhat difficult to interpret. The Jadad scores of the studies were very low, reflecting problems in trial design, execution, and reporting that could be addressed in a fairly straightforward way with further education in the traditional Chinese medicine research community.
An even greater challenge is posed by the wide variety of herbal formulas used: only 2 of 26 studies looked at the same formula. What is the correct way to proceed from here in the investigation of Chinese herbal medicine combined with cancer? The path toward assembling a single formula that could be tested in large randomized studies is not at all clear. What I know would clearly not best serve the interests of patients, though, would be to implement the Western impulse to break the formulas down into their individual constituent herbs and test each one separately to investigate its pharmacology, best means of standardization, drug interaction potential, and optimal dosage and then put them back together into a single formula that could be used in a randomized trial based on these data. A more likely way to proceed would be through a consensus process to evaluate traditional knowledge about the overall effects of each of the formulas-a type of knowledge that integrates long-term empirical observations based on pharmacology, dosing, and interactions, as well as mechanisms that science may not yet comprehend at all. This would not be easy but would probably result in a more realistic assessment of the potentials of traditional herbal formulas. This problem is just one of the many difficulties that reminds us that the challenges of research in integrative and traditional medicine should not be underestimated.
Philip Tovey and colleagues have contributed two articles from another less-developed country. Until now, little has been heard from Pakistan in the area of traditional and complementary medicine. Their first article introduces the types of traditional and alternative healing systems that are available in Pakistan while the second presents results of a survey of cancer patients' attitudes toward the medical systems that are available to them as they cope with their malignancies. Interestingly, in addition to the indigenous traditional systems, some CAM systems that are widely available globally have taken root in Pakistan. The most widely used of these in Pakistan is homeopathy, which is discussed further in the second article. A strong system of spiritual healing is found in Pakistan, and this evidently provides a great deal of comfort and satisfaction to cancer patients in that country.
The spiritual aspects of healing are discussed in a Western context in the article by Nancy Dann and colleagues from the Baystate Regional Cancer Center. These authors designed a nondenominational worship service for persons touched by cancer. The service was held in several Christian churches in surrounding communities. The authors explore reactions of attendees at these services, assessing their preferences according to gender, religious affiliation, and whether they were patients themselves or family members of cancer patients. Such a systematic attempt to reach out to people wrestling with the spiritual aspects of cancer, which are, in vivid contrast to Pakistan, frequently neglected in the United States, is certainly welcome. An attempt to expand this kind of service in other communities and in religious centers of different denominations would certainly be a good follow-up to such a study. I hope that pastoral counseling staff at other cancer centers take note of the reactions that Dann and colleagues report and work on developing similar outreach services at their own hospitals.
The Integrative Tumor Board in this issue examines a patient with malignant melanoma, as described by Deva Nathan, MD. In addition to the herbal contribution mentioned above, articles by Michael Uzick on naturopathy and Penny Block on mind-spirit care comprise the Tumor Board panel. One of the interesting questions that arose as I examined these contributions was whether St John's wort might be prescribed for the depression that often accompanies high-dose interferon, a standard melanoma therapy. Of course, an important consideration was the possibility of a drug interaction due to the induction of cytochrome P450 enzymes by St John's wort. Somewhat to my surprise, I found that St John's wort does not appear to affect interferon availability. It is interesting enough that we do know something about the pharmacokinetics of some of the active compounds in St John's wort (both hyperforin and hypericin). What is even more intriguing is the sense of being a bit surprised that St John's wort had no negative effect on interferon. The mainstream medical press and lay media are so eager now to pounce on any indication of harmful effects of herbal medicines or other alternative therapies that we all, I think, start to anticipate them even if they are never reported. David Winston, author of the herbal therapy contribution in this Tumor Board, told a member of Integrative Cancer Therapies's editorial staff, in discussions about preparing his article, that physicians used to telephone him to ask what different herbal medicines were and whether they could possibly have any helpful effects on their patients. Now they call to ask him whether herbs are going to kill their patients. While we do need to be mindful of the fact that herbs can have side effects and drug interactions just like any other type of medication, I think the degree of abreaction over these possibilities is inconsistent with the existing literature and extensive global history. I, for one, look forward to the time when integrative cancer care moves beyond this period where reactionary positions are taken, a common stage occurring with any paradigm shift. We at Integrative Cancer Therapies encourage and welcome discussion and contributions on this topic.
